Jim Simons Tempest Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.3 - $1.39 $4,470 - $20,712	-14,901 Reduced 14.41%	88,500 $27,000
Q2 2023 Aug 11, 2023	BUY	$1.12 - $3.76 $86,129 - $289,147	76,901 Added 290.19%	103,401 $131,000
Q1 2023 May 12, 2023	BUY	$1.14 - $2.91 $1,254 - $3,201	1,100 Added 4.33%	26,500 $61,000
Q4 2022 Feb 13, 2023	SELL	$1.15 - $2.12 $1,839 - $3,392	-1,600 Reduced 5.93%	25,400 $29,000
Q3 2022 Nov 14, 2022	SELL	$1.62 - $2.76 $486 - $827	-300 Reduced 1.1%	27,000 $47,000
Q2 2022 Aug 12, 2022	SELL	$2.08 - $4.15 $26,817 - $53,505	-12,893 Reduced 32.08%	27,300 $59,000
Q1 2022 May 13, 2022	SELL	$2.27 - $5.45 $23,237 - $55,791	-10,237 Reduced 20.3%	40,193 $136,000
Q4 2021 Feb 11, 2022	BUY	$5.28 - $15.2 $86,201 - $248,155	16,326 Added 47.87%	50,430 $266,000
Q3 2021 Nov 12, 2021	BUY	$10.49 - $24.19 $75,916 - $175,063	7,237 Added 26.94%	34,104 $493,000
Q2 2021 Aug 13, 2021	BUY	$11.18 - $22.95 $300,373 - $616,597	26,867 New	26,867 $300,000

2.46M

44.9K

109K

Ticker TPST
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 10,418,900
Market Cap $9.59M
Description
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxiso...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.